Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Shiells

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Neuroscience Methods|February 25, 2015
Network inference in the presence of latent confounders: the role of instantaneous causalitiesHeba Elsegai, Helen Shiells, Marco Thiel, et al.
Scientific Reports|January 11, 2025
Obtaining personalized predictions from a randomized controlled trial on Alzheimer's diseaseDennis Shen, Anish Agarwal, Vishal Misra, et al.
Journal of Alzheimer'S Disease : JAD|August 9, 2021
Long-Term Hydromethylthionine Treatment Is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-Symptomatic P301S MAPT Mutation CarrierPeter Bentham, Roger T Staff, Bjoern O Schelter, et al.
Current Alzheimer Research|January 5, 2026
Hypertension is the Main Vascular Risk Factor for Cognitive Impairment, Microvascular Pathology and Brain Atrophy in Alzheimer's DiseaseShailendra Mohan Tripathi, Helen Shiells, Jennifer Waymont, et al.
International Journal of Molecular Sciences|September 28, 2023
Exploring the Anti-Hypoxaemia Effect of Hydromethylthionine: A Prospective Study of Phase 3 Clinical Trial ParticipantsMohammad Arastoo, Michael P Mazanetz, Sonya Miller, et al.
British Journal of Clinical Pharmacology|April 1, 2026
Atypical population pharmacokinetics of hydromethylthionine in patients with Alzheimer's disease explains unexpected phase 3 trial resultsEline van Maanen, Antonio Gonçalves, Lu Chen, et al.
Journal of Alzheimer'S Disease : JAD|October 29, 2019
Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's DiseaseBjoern O Schelter, Helen Shiells, Thomas C Baddeley, et al.
Journal of Alzheimer'S Disease : JAD|April 14, 2020
Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal DementiaHelen Shiells, Bjoern O Schelter, Peter Bentham, et al.
The Journal of Prevention of Alzheimer'S Disease|April 18, 2026
Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer's disease with hydromethylthionine mesylate using external control dataBjoern O Schelter, Helen Shiells, Serena Lo, et al.
The Journal of Prevention of Alzheimer'S Disease|January 22, 2026
Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's diseaseClaude M Wischik, Richard Stefanacci, Peter Bentham, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Neuroscience Methods|February 25, 2015
Network inference in the presence of latent confounders: the role of instantaneous causalitiesHeba Elsegai, Helen Shiells, Marco Thiel, et al.
Scientific Reports|January 11, 2025
Obtaining personalized predictions from a randomized controlled trial on Alzheimer's diseaseDennis Shen, Anish Agarwal, Vishal Misra, et al.
Journal of Alzheimer'S Disease : JAD|August 9, 2021
Long-Term Hydromethylthionine Treatment Is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-Symptomatic P301S MAPT Mutation CarrierPeter Bentham, Roger T Staff, Bjoern O Schelter, et al.
Current Alzheimer Research|January 5, 2026
Hypertension is the Main Vascular Risk Factor for Cognitive Impairment, Microvascular Pathology and Brain Atrophy in Alzheimer's DiseaseShailendra Mohan Tripathi, Helen Shiells, Jennifer Waymont, et al.
International Journal of Molecular Sciences|September 28, 2023
Exploring the Anti-Hypoxaemia Effect of Hydromethylthionine: A Prospective Study of Phase 3 Clinical Trial ParticipantsMohammad Arastoo, Michael P Mazanetz, Sonya Miller, et al.
British Journal of Clinical Pharmacology|April 1, 2026
Atypical population pharmacokinetics of hydromethylthionine in patients with Alzheimer's disease explains unexpected phase 3 trial resultsEline van Maanen, Antonio Gonçalves, Lu Chen, et al.
Journal of Alzheimer'S Disease : JAD|October 29, 2019
Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's DiseaseBjoern O Schelter, Helen Shiells, Thomas C Baddeley, et al.
Journal of Alzheimer'S Disease : JAD|April 14, 2020
Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal DementiaHelen Shiells, Bjoern O Schelter, Peter Bentham, et al.
The Journal of Prevention of Alzheimer'S Disease|April 18, 2026
Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer's disease with hydromethylthionine mesylate using external control dataBjoern O Schelter, Helen Shiells, Serena Lo, et al.
The Journal of Prevention of Alzheimer'S Disease|January 22, 2026
Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's diseaseClaude M Wischik, Richard Stefanacci, Peter Bentham, et al.
Pageof 1